Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Keytruda TM

Listen to the Pronunciation:

Active ingredients: pembrolizumab

What it is used for

Melanoma,KEYTRUDA® (pembrolizumab) is indicated as monotherapy for the treatment of unresectable or metastatic melanoma in adults.,KEYTRUDA® (pembrolizumab) is indicated as monotherapy for the adjuvant treatment of patients with melanoma with lymph node involvement who have undergone complete resection.,Non-small cell lung cancer (NSCLC),KEYTRUDA® (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations.,KEYTRUDA® (pembrolizumab), in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.,KEYTRUDA® (pembrolizumab) is indicated as monotherapy for the first-line treatment of patients with NSCLC expressing PD-L1 [tumour proportion score (TPS) greater than or equal to 1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and is;, stage III where patients are not candidates for surgical resection or definitive chemoradiation, or, metastatic.,KEYTRUDA® (pembrolizumab) is indicated as monotherapy for the treatment of patients with advanced NSCLC whose tumours express PD-L1 with a greater than or equal to 1% TPS as determined by a validated test and who have received platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received prior therapy for these aberrations prior to receiving KEYTRUDA.,Head and Neck Squamous Cell Cancer (HNSCC),KEYTRUDA® (pembrolizumab), as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of patients with metastatic or unresectable recurrent HNSCC, and whose tumours express PD-L1 [Combined Positive Score (CPS) greater than or equal to 1] as determined by a validated test.,KEYTRUDA® (pembrolizumab) is indicated as monotherapy for the treatment of patients with metastatic or unresectable recurrent HNSCC with disease progression on or after platinum-containing chemotherapy and whose tumours express PD-L1 [Combined Positive Score (CPS) greater than or equal to 1] as determined by a validated test.,Classical Hodgkin Lymphoma (cHL),KEYTRUDA® (pembrolizumab) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL):,1. following autologous stem cell transplant (ASCT) or,2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.,The approval of this indication is on the basis of objective response rate (ORR). See Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials.,Primary mediastinal B-Cell Lymphoma (PMBCL),KEYTRUDA® (pembrolizumab) is indicated for the treatment of adult and paediatric patients with refractory primary mediastinal B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. The approval of this indication is on the basis of objective response rate (ORR) and duration of response from non-randomised studies. See Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials.,Urothelial carcinoma,KEYTRUDA® (pembrolizumab) is indicated as monotherapy for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing therapy and whose tumours express PD-L1 [Combined Positive Score (CPS) greater than or equal to 10] as determined by a validated test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved based on overall response rate and duration of response in a single-arm study. Improvements in overall survival, progression-free survival, or health-related quality of life have not been established.,KEYTRUDA® (pembrolizumab) is indicated as monotherapy for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received platinum-containing chemotherapy.,Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer,Colorectal (previously untreated),KEYTRUDA® (pembrolizumab) is indicated for the first-line treatment of patients with unresectable or metastatic colorectal cancer (CRC) that is MSI-H or dMMR as determined by a validated test.,Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer - Provisionally Registered Indications,Colorectal (previously treated),KEYTRUDA® (pembrolizumab) is indicated in adult and paediatric patients for the treatment of unresectable or metastatic CRC that is MSI-H or dMMR as determined by a validated test, and that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication was approved via the provisional approval pathway, based on objective response rate and response duration in a single-arm trial. Continued approval for this indication depends on verification and description of clinical benefit in the confirmatory trials.,Non-colorectal,KEYTRUDA® (pembrolizumab) is indicated in adult and paediatric patients for the treatment of unresectable or metastatic solid tumours that are MSI-H or dMMR as determined by a validated test, that have progressed following prior treatment and when there are no satisfactory alternative treatment options. This indication was approved via the provisional approval pathway, based on the pooling of data on objective response rate and response duration across multiple different tissue types in a single-arm trial. Sample sizes for individual tissue types were too small to provide data on clinical utility of the MSI-H/dMMR tests for each of the tissue types, individually. The assumption that MSI-H/dMMR-status is predictive of the treatment effect of KEYTRUDA for every tissue type has not been verified. Continued approval for this indication depends on verification and description of clinical benefit in the confirmatory trials.,The safety and effectiveness of KEYTRUDA in paediatric patients with MSI-H/dMMR central nervous system cancers have not been established.,Endometrial carcinoma,KEYTRUDA® (pembrolizumab), in combination with lenvatinib, is indicated for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR as determined by a validated test, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation. This indication was approved via the provisional approval pathway, based on objective response rate and duration of response in a single-arm trial. Full registration for this indication depends on verification and description of clinical benefit in confirmatory trials.,Renal Cell Carcinoma (RCC),KEYTRUDA® (pembrolizumab), in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

How to take it

The way to take this medicine is: Intravenous Infusion.

  • Store at 2 to 8 degrees Celsius
  • Refrigerate
  • Do not Freeze
  • Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

powder for injection supplied as a white to off-white cake,contained within 15mL glass vials.

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

Pregnant or planning a pregnancy?

For the active ingredient pembrolizumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Consumer Medicines Information (CMI)

For side effects, taking other medicines and more

Print the CMI.

Listen to the CMI.


Reporting side effects

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.

Back to top back to top

Need more information?

These trusted information partners have more on this topic.

Healthdirect 24hr 7 days a week hotline

24 hour health advice you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information and advice

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo